Home › BioCryst Pharmaceuticals Downgraded to Underperform at Bank of America
 

Keywords :   


BioCryst Pharmaceuticals Downgraded to Underperform at Bank of America

2015-11-16 05:33:57| Biotech - Topix.net

They presently have a $10.00 price target on the biotechnology company's stock, down from their previous price target of $12.00. Bank of America's price objective would indicate a potential upside of 3.95% from the stock's previous close.

Tags: america bank pharmaceuticals downgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.07Tropical Storm Beryl Public Advisory Number 33
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Tropical Storm Beryl Public Advisory Number 32A
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Eastern North Pacific Tropical Weather Outlook
06.07Atlantic Tropical Weather Outlook
06.07Axalta Schedules Second-Quarter 2024 Earnings Conference Call
06.07Tropical Storm Beryl Potential Storm Surge Flooding Map
More »